Health-related quality of life for octreotide long-acting vs. placebo in patients with metastatic midgut neuroendocrine tumors in the phase 3 PROMID trial

Conclusions HRQoL was maintained with few deteriorations in octreotide long-acting patients, whereas there was earlier and/or more deterioration in placebo patients. In octreotide long-acting patients, HRQoL was maintained or improved for the clinically important NET symptoms such as fatigue, insomnia, diarrhea and pain, whereas placebo patients experienced a deterioration of HRQoL on these symptoms.

https://www.karger.com/Article/FullText/499469

Source: Neuroendocrinology - March 11, 2019 Category: Endocrinology Source Type: research